总局明确豁免临床试验IVD试剂临床评价资料要求

2017-11-10 马艳红 中国医药报

继10月30日,国家食品药品监管总局发布第三批免于进行临床试验的医疗器械目录(以下简称“目录”),对37种第二类医疗器械、11种第三类医疗器械和116种体外诊断(IVD)试剂豁免进行临床试验后,日前,总局又发布《免于进行临床试验的体外诊断试剂临床评价资料基本要求(试行)》(以下简称《基本要求》),并于发布之日起施行。《基本要求》配合目录使用,用于指导注册申请人进行体外诊断试剂临床评价工作。这是总局

继10月30日,国家食品药品监管总局发布第三批免于进行临床试验的医疗器械目录(以下简称“目录”),对37种第二类医疗器械、11种第三类医疗器械和116种体外诊断(IVD)试剂豁免进行临床试验后,日前,总局又发布《免于进行临床试验的体外诊断试剂临床评价资料基本要求(试行)》(以下简称《基本要求》),并于发布之日起施行。《基本要求》配合目录使用,用于指导注册申请人进行体外诊断试剂临床评价工作。这是总局贯彻落实中办、国办《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》,深入推进“放管服”改革,推进基于风险的产品评价方式,优化配置临床试验和审评审批资源,促进安全有效、风险可控的产品尽快上市的又一改革举措。

根据2014年发布的《体外诊断试剂注册管理办法》(以下简称《办法》)第二十九条,无需进行临床试验的体外诊断试剂,申请人或者备案人应当通过对涵盖预期用途及干扰因素的临床样本的评估、综合文献资料等非临床试验的方式,对体外诊断试剂的临床性能进行评价。

记者了解到,今年年初,《基本要求》制订工作启动。制订过程中,总局充分征求意见,收到来自医院、协会、企业、个人、省局和总局等30余家单位的130条意见。在对相关反馈意见进行梳理和研究,并综合各方建议、参考国内外相关指南文件后,总局对征求意见稿中未明确或存在异议的内容进行修改完善,经反复商榷,最终制定并发布实施《基本要求》。

《基本要求》的内容包括适用范围、基本要求、临床评价途径、试验方法、临床评价报告、其他评价资料6章,涵盖临床评价试验的基本要求及申报资料的相关要求。

总局在发布《基本要求》的同时还进行了政策解读,明确《基本要求》的3项主要内容:一是突出了申请人主体责任。《基本要求》明确,申请人自行或委托其他机构或实验室在中国境内完成临床评价工作,试验过程由申请人进行管理,评价报告应由申请人/代理人签章,试验数据的真实性由申请人负责。二是强调了样本来源追溯性要求。要求评价用样本(病例)原始资料中应至少包括样本来源、唯一且可追溯的编号、年龄、性别、样本类型、样本临床背景信息等内容。三是明确了临床评价的试验方法。可参考相关方法学比对的指导原则开展试验,并根据产品特点选择合适的统计学方法进行统计分析,以求得到客观可信的结果。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1966837, encodeId=4455196683e59, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Sep 12 13:41:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263467, encodeId=4f2126346e65, content=学了......, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Wed Nov 22 23:53:13 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262992, encodeId=640626299279, content=学了......, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Tue Nov 21 06:02:35 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262937, encodeId=436226293e39, content=学了......., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Mon Nov 20 22:58:35 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261534, encodeId=8cf426153415, content=学了......., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Wed Nov 15 21:05:34 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367977, encodeId=5283136e9775f, content=<a href='/topic/show?id=e61310130f5' target=_blank style='color:#2F92EE;'>#IVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10130, encryptionId=e61310130f5, topicName=IVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Nov 12 05:41:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444291, encodeId=77881444291ce, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Nov 12 05:41:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260302, encodeId=2c722603027f, content=继10月30日.国家食品药品监管总局发布第三批免于进行临床试验的医疗器械目录(以下简称[目录").对37种第二类医疗器械.11种第三类医疗器械和116种体外诊断(IVD)试剂豁免进行临床试验后.日前.总局又发布<免于进行临床试验的体外诊断试剂临床评价资料基本要求(试行)>(以下简称<基本要求>).并于发布之日起施行., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Nov 10 16:40:02 CST 2017, time=2017-11-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1966837, encodeId=4455196683e59, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Sep 12 13:41:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263467, encodeId=4f2126346e65, content=学了......, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Wed Nov 22 23:53:13 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262992, encodeId=640626299279, content=学了......, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Tue Nov 21 06:02:35 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262937, encodeId=436226293e39, content=学了......., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Mon Nov 20 22:58:35 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261534, encodeId=8cf426153415, content=学了......., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Wed Nov 15 21:05:34 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367977, encodeId=5283136e9775f, content=<a href='/topic/show?id=e61310130f5' target=_blank style='color:#2F92EE;'>#IVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10130, encryptionId=e61310130f5, topicName=IVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Nov 12 05:41:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444291, encodeId=77881444291ce, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Nov 12 05:41:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260302, encodeId=2c722603027f, content=继10月30日.国家食品药品监管总局发布第三批免于进行临床试验的医疗器械目录(以下简称[目录").对37种第二类医疗器械.11种第三类医疗器械和116种体外诊断(IVD)试剂豁免进行临床试验后.日前.总局又发布<免于进行临床试验的体外诊断试剂临床评价资料基本要求(试行)>(以下简称<基本要求>).并于发布之日起施行., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Nov 10 16:40:02 CST 2017, time=2017-11-10, status=1, ipAttribution=)]
    2017-11-22 135****7952平儿

    学了......

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1966837, encodeId=4455196683e59, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Sep 12 13:41:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263467, encodeId=4f2126346e65, content=学了......, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Wed Nov 22 23:53:13 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262992, encodeId=640626299279, content=学了......, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Tue Nov 21 06:02:35 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262937, encodeId=436226293e39, content=学了......., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Mon Nov 20 22:58:35 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261534, encodeId=8cf426153415, content=学了......., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Wed Nov 15 21:05:34 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367977, encodeId=5283136e9775f, content=<a href='/topic/show?id=e61310130f5' target=_blank style='color:#2F92EE;'>#IVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10130, encryptionId=e61310130f5, topicName=IVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Nov 12 05:41:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444291, encodeId=77881444291ce, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Nov 12 05:41:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260302, encodeId=2c722603027f, content=继10月30日.国家食品药品监管总局发布第三批免于进行临床试验的医疗器械目录(以下简称[目录").对37种第二类医疗器械.11种第三类医疗器械和116种体外诊断(IVD)试剂豁免进行临床试验后.日前.总局又发布<免于进行临床试验的体外诊断试剂临床评价资料基本要求(试行)>(以下简称<基本要求>).并于发布之日起施行., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Nov 10 16:40:02 CST 2017, time=2017-11-10, status=1, ipAttribution=)]
    2017-11-21 135****7952平儿

    学了......

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1966837, encodeId=4455196683e59, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Sep 12 13:41:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263467, encodeId=4f2126346e65, content=学了......, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Wed Nov 22 23:53:13 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262992, encodeId=640626299279, content=学了......, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Tue Nov 21 06:02:35 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262937, encodeId=436226293e39, content=学了......., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Mon Nov 20 22:58:35 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261534, encodeId=8cf426153415, content=学了......., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Wed Nov 15 21:05:34 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367977, encodeId=5283136e9775f, content=<a href='/topic/show?id=e61310130f5' target=_blank style='color:#2F92EE;'>#IVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10130, encryptionId=e61310130f5, topicName=IVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Nov 12 05:41:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444291, encodeId=77881444291ce, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Nov 12 05:41:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260302, encodeId=2c722603027f, content=继10月30日.国家食品药品监管总局发布第三批免于进行临床试验的医疗器械目录(以下简称[目录").对37种第二类医疗器械.11种第三类医疗器械和116种体外诊断(IVD)试剂豁免进行临床试验后.日前.总局又发布<免于进行临床试验的体外诊断试剂临床评价资料基本要求(试行)>(以下简称<基本要求>).并于发布之日起施行., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Nov 10 16:40:02 CST 2017, time=2017-11-10, status=1, ipAttribution=)]
    2017-11-20 135****7952平儿

    学了.......

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1966837, encodeId=4455196683e59, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Sep 12 13:41:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263467, encodeId=4f2126346e65, content=学了......, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Wed Nov 22 23:53:13 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262992, encodeId=640626299279, content=学了......, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Tue Nov 21 06:02:35 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262937, encodeId=436226293e39, content=学了......., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Mon Nov 20 22:58:35 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261534, encodeId=8cf426153415, content=学了......., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Wed Nov 15 21:05:34 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367977, encodeId=5283136e9775f, content=<a href='/topic/show?id=e61310130f5' target=_blank style='color:#2F92EE;'>#IVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10130, encryptionId=e61310130f5, topicName=IVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Nov 12 05:41:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444291, encodeId=77881444291ce, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Nov 12 05:41:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260302, encodeId=2c722603027f, content=继10月30日.国家食品药品监管总局发布第三批免于进行临床试验的医疗器械目录(以下简称[目录").对37种第二类医疗器械.11种第三类医疗器械和116种体外诊断(IVD)试剂豁免进行临床试验后.日前.总局又发布<免于进行临床试验的体外诊断试剂临床评价资料基本要求(试行)>(以下简称<基本要求>).并于发布之日起施行., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Nov 10 16:40:02 CST 2017, time=2017-11-10, status=1, ipAttribution=)]
    2017-11-15 135****7952平儿

    学了.......

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1966837, encodeId=4455196683e59, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Sep 12 13:41:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263467, encodeId=4f2126346e65, content=学了......, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Wed Nov 22 23:53:13 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262992, encodeId=640626299279, content=学了......, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Tue Nov 21 06:02:35 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262937, encodeId=436226293e39, content=学了......., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Mon Nov 20 22:58:35 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261534, encodeId=8cf426153415, content=学了......., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Wed Nov 15 21:05:34 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367977, encodeId=5283136e9775f, content=<a href='/topic/show?id=e61310130f5' target=_blank style='color:#2F92EE;'>#IVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10130, encryptionId=e61310130f5, topicName=IVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Nov 12 05:41:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444291, encodeId=77881444291ce, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Nov 12 05:41:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260302, encodeId=2c722603027f, content=继10月30日.国家食品药品监管总局发布第三批免于进行临床试验的医疗器械目录(以下简称[目录").对37种第二类医疗器械.11种第三类医疗器械和116种体外诊断(IVD)试剂豁免进行临床试验后.日前.总局又发布<免于进行临床试验的体外诊断试剂临床评价资料基本要求(试行)>(以下简称<基本要求>).并于发布之日起施行., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Nov 10 16:40:02 CST 2017, time=2017-11-10, status=1, ipAttribution=)]
    2017-11-12 yourmama
  7. [GetPortalCommentsPageByObjectIdResponse(id=1966837, encodeId=4455196683e59, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Sep 12 13:41:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263467, encodeId=4f2126346e65, content=学了......, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Wed Nov 22 23:53:13 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262992, encodeId=640626299279, content=学了......, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Tue Nov 21 06:02:35 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262937, encodeId=436226293e39, content=学了......., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Mon Nov 20 22:58:35 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261534, encodeId=8cf426153415, content=学了......., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Wed Nov 15 21:05:34 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367977, encodeId=5283136e9775f, content=<a href='/topic/show?id=e61310130f5' target=_blank style='color:#2F92EE;'>#IVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10130, encryptionId=e61310130f5, topicName=IVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Nov 12 05:41:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444291, encodeId=77881444291ce, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Nov 12 05:41:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260302, encodeId=2c722603027f, content=继10月30日.国家食品药品监管总局发布第三批免于进行临床试验的医疗器械目录(以下简称[目录").对37种第二类医疗器械.11种第三类医疗器械和116种体外诊断(IVD)试剂豁免进行临床试验后.日前.总局又发布<免于进行临床试验的体外诊断试剂临床评价资料基本要求(试行)>(以下简称<基本要求>).并于发布之日起施行., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Nov 10 16:40:02 CST 2017, time=2017-11-10, status=1, ipAttribution=)]
    2017-11-12 huagfeg
  8. [GetPortalCommentsPageByObjectIdResponse(id=1966837, encodeId=4455196683e59, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Sep 12 13:41:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263467, encodeId=4f2126346e65, content=学了......, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Wed Nov 22 23:53:13 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262992, encodeId=640626299279, content=学了......, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Tue Nov 21 06:02:35 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262937, encodeId=436226293e39, content=学了......., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Mon Nov 20 22:58:35 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261534, encodeId=8cf426153415, content=学了......., beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Wed Nov 15 21:05:34 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367977, encodeId=5283136e9775f, content=<a href='/topic/show?id=e61310130f5' target=_blank style='color:#2F92EE;'>#IVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10130, encryptionId=e61310130f5, topicName=IVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Nov 12 05:41:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444291, encodeId=77881444291ce, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun Nov 12 05:41:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260302, encodeId=2c722603027f, content=继10月30日.国家食品药品监管总局发布第三批免于进行临床试验的医疗器械目录(以下简称[目录").对37种第二类医疗器械.11种第三类医疗器械和116种体外诊断(IVD)试剂豁免进行临床试验后.日前.总局又发布<免于进行临床试验的体外诊断试剂临床评价资料基本要求(试行)>(以下简称<基本要求>).并于发布之日起施行., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Nov 10 16:40:02 CST 2017, time=2017-11-10, status=1, ipAttribution=)]
    2017-11-10 有备才能无患

    继10月30日.国家食品药品监管总局发布第三批免于进行临床试验的医疗器械目录(以下简称[目录").对37种第二类医疗器械.11种第三类医疗器械和116种体外诊断(IVD)试剂豁免进行临床试验后.日前.总局又发布<免于进行临床试验的体外诊断试剂临床评价资料基本要求(试行)>(以下简称<基本要求>).并于发布之日起施行.

    0

相关资讯

FDA宣布将“扩大获取计划”扩展至罕见病患者

一项旨在挽救晚期肿瘤患者的同情用药计划,如今罕见病患者也可以适用。

《免于进行临床试验的体外诊断试剂临床评价资料基本要求(试行)》解读

国家食品药品监督管理总局组织制定并于2017年11月3日发布了《免于进行临床试验的体外诊断试剂临床评价资料基本要求(试行)》,自发布之日起施行。

CLIN CANCER RES:Trebananib用于治疗儿童复发实体肿瘤及原发神经系统肿瘤的Ⅰ期临床试验结果

Trebananib是抑制血管生成素1和2的一线抗血管生成抗体。CLIN CANCER RES近期发表了一篇文章,报道了Trebananib用于治疗儿童肿瘤的Ⅰ期临床试验结果,包括剂量限制毒性(DLT)、推荐Ⅱ期试验剂量(RP2D)和药代动力学等。

烧伤病人或无需“割肉补疮”:国产“人工真皮”进入临床试验

从浙江大学医学院附属第二医院获悉,该院烧伤科团队研制的人工真皮已进入临床试验阶段,最快三年可面世。

临床试验希望为前列腺癌提供毒性较小的治疗

在过去的十年中,免疫疗法已经成为肿瘤学领域最有前途和创新的领域之一。免疫疗法的目标是利用患者自身的免疫系统对抗癌症。2010年,美国食品和药物管理局(FDA)批准了第一种癌症治疗疫苗sipuleucel - T(品牌名称来源),用于治疗前列腺癌。Roswell Park癌症研究所泌尿生殖医学临床主任Gurkamal Chatta博士说:"从那时起,已经有其他免疫治疗前列腺癌的临床试验,但是我们还没

3期结果积极,肠易激综合征新药拟明年申请上市

Ardelyx公司近日公开了一项3期临床试验T3MPO-2的积极结果,这是使用tenapanor治疗便秘型肠易激综合征(IBS-C)的第二项3期临床试验。这项研究统计学显著达到了主要终点和所有次要终点,并展现了其可使患者正常排便的能力。